PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1749643
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1749643
Neuroprotection Market Size - By Type, By Application, By Mode of Administration, By End-Users- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Neuroprotection Market Introduction and Overview
According to SPER Market Research, 'Global Neuroprotection Market Size - By Type, By Application, By Mode of Administration, By End-Users- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Neuroprotection Market is predicted to reach 147.21 billion by 2034 with a CAGR of 7.61%.
The word "neuroprotection" refers to strategies and mechanisms that protect the nervous system, and particularly neurons, against damage, malfunction, and degradation caused by a range of circumstances, including as disease, trauma, and being exposed to toxins. In order to prevent the loss of neurons brought on by conditions which includes Parkinson's disease, multiple sclerosis, Alzheimer's disease, and stroke, neuroprotection focuses on maintaining the structure and function of brain cells.
Restraints: The neuroprotection market is anticipated to grow, but there are some significant barriers that may prevent it from doing so. Developing neuroprotective therapies requires navigating complex and precise regulatory pathways. To guarantee the safety and efficacy of these medications, extensive research and meticulous data collection are necessary, and they can be costly and time-consuming. The expense of conducting research and developing neuroprotective drugs is high.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Type, By Application, By Mode of Administration, By End-Users
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Allergan, AstraZeneca, Astrocyte Pharmaceuticals, Biogen, Daiichi Sankyo Company, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Novartis, Teva Pharmaceutical Industries.
Global Neuroprotection Market Segmentation:
By Type: Based on the Type, Global Neuroprotection Market is segmented as; Free Anti-Inflammatory Agents, Radical Trapping Agents (Antioxidants), Apoptosis Inhibitors, Glutamate Antagonists (Anti-Excitotoxic Agents), Neurotrophic Factors (NTFs), Stimulants, Metal Ion Chelators, Other.
By Application: Based on the Application, Global Neuroprotection Market is segmented as; Prevention, Treatment.
By Mode of Administration: Based on the Mode of Administration, Global Neuroprotection Market is segmented as; Oral, Intravenous, Others.
By End-Users: Based on the End-Users, Global Neuroprotection Market is segmented as; Hospitals, Clinics, Home Care Settings, Research Institutes.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER's internal database
2.1.4. Premium insight from KOL's
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER's Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Neuroprotection Market Manufacturing Base Distribution, Sales Area, Interface Type
6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Neuroprotection Market
7. Global Neuroprotection Market, By Type 2021-2034 (USD Million)
7.1. Free Anti-Inflammatory Agents
7.2. Radical Trapping Agents (Antioxidants)
7.3. Apoptosis Inhibitors
7.4. Glutamate Antagonists (Anti-Excitotoxic Agents)
7.5. Neurotrophic Factors (NTFs)
7.6. Stimulants
7.7. Metal Ion Chelators
7.8. Other
8. Global Neuroprotection Market, By Application 2021-2034 (USD Million)
8.1. Prevention
8.2. Treatment
9. Global Neuroprotection Market, By Mode of Administration 2021-2034(USD Million)
9.1. Oral
9.2. Intravenous
9.3. Others
10. Global Neuroprotection Market, By End-Users 2021-2034 (USD Million)
10.1. Hospitals
10.2. Clinics
10.3. Home Care Settings
10.4. Research Institutes
11. Global Neuroprotection Market, 2021-2034 (USD Million)
11.1. Global Neuroprotection Market Size and Market Share
12. Global Neuroprotection Market, By Region, 2021-2034 (USD Million)
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Allergan
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Interface summary
13.1.4. Recent developments
13.2. AstraZeneca
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Interface summary
13.2.4. Recent developments
13.3. Astrocyte Pharmaceuticals
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Interface summary
13.3.4. Recent developments
13.4. Biogen
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Interface summary
13.4.4. Recent developments
13.5. Daiichi Sankyo Company
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Interface summary
13.5.4. Recent developments
13.6. Dr. Reddy's Laboratories
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Interface summary
13.6.4. Recent developments
13.7. Eli Lilly and Company
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Interface summary
13.7.4. Recent developments
13.8. F. Hoffmann-La Roche
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Interface summary
13.8.4. Recent developments
13.9. Novartis
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Interface summary
13.9.4. Recent developments
13.10. Teva Pharmaceutical Industries
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Interface summary
13.10.4. Recent developments
14. Conclusion
15. List of Abbreviations
16. Reference Links
